Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

(131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma.

Trial Profile

(131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma.

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Iobenguane (Primary) ; Carbidopa; Isotretinoin; Methylprednisolone; Metirosine; Potassium
  • Indications Neuroblastoma; Phaeochromocytoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2010 Planned end date (Jul 2015) added as reported by ClinicalTrials.gov (NCT01163383).
    • 14 Jul 2010 Planned patient number is 250 according to ClinicalTrials.gov (NCT01163383).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top